VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
P/S ratio for VectivBio Holding AG (VECT)
P/S ratio as of 2022: 13.98
According to VectivBio Holding AG's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 13.98. At the end of 2021 the company had a P/S ratio of 0.00.
P/S ratio history for VectivBio Holding AG from 2018 to 2022
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2022 | 13.98 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |